Research location
Redlands
California, United States
Advertisement
Research activity in Redlands
California, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 154 trials and 156 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Redlands
154 linked trials · page 2 of 4A Clinical Trial of PRAX-114 in Participants With Major Depressive DisorderNCT04832425 · 2021-03-30 · 1 site observation
COMPLETED
A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)NCT04374253 · 2021-01-26 · 1 site observation
TERMINATED
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)NCT04602624 · 2020-12-07 · 1 site observation
COMPLETED
MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular HypertensionNCT04630808 · 2020-11-09 · 1 site observation
COMPLETED
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)NCT04611152 · 2020-09-30 · 1 site observation
TERMINATED
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)NCT04634669 · 2020-09-23 · 1 site observation
TERMINATED
A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant TherapyNCT04513912 · 2020-09-15 · 1 site observation
COMPLETED
Mechanistic Evaluation of Response in TRD (MERIT)NCT04608396 · 2020-08-13 · 1 site observation
COMPLETED
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)NCT04437511 · 2020-06-19 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)NCT04442503 · 2020-06-08 · 1 site observation
COMPLETED
A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)NCT04442490 · 2020-05-12 · 1 site observation
COMPLETED
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205NCT04241068 · 2020-03-02 · 1 site observation
TERMINATED
A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast CancerNCT04031885 · 2019-08-14 · 1 site observation
TERMINATED
Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular EdemaNCT03917472 · 2019-07-17 · 1 site observation
COMPLETED
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung CancerNCT03906071 · 2019-07-15 · 1 site observation
TERMINATED
Open-Label Safety Study of AXS-05 in Subjects With DepressionNCT04039022 · 2019-07-08 · 1 site observation
COMPLETED
A Trial of AXS-05 in Patients With Major Depressive DisorderNCT04019704 · 2019-06-20 · 1 site observation
COMPLETED
A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive DisorderNCT03672175 · 2018-11-19 · 1 site observation
COMPLETED
The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants AloneNCT03739203 · 2018-11-10 · 1 site observation
COMPLETED
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants AloneNCT03738215 · 2018-11-09 · 1 site observation
COMPLETED
Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast CancerNCT03499353 · 2018-08-27 · 1 site observation
TERMINATED
Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)NCT03443973 · 2018-08-22 · 1 site observation
TERMINATED
A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)NCT03610048 · 2018-08-09 · 1 site observation
TERMINATED
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's DiseaseNCT03518073 · 2018-04-30 · 1 site observation
COMPLETED
An Open-Label Crenezumab Study in Participants With Alzheimer's DiseaseNCT03491150 · 2018-04-11 · 1 site observation
TERMINATED
Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung CancerNCT03382899 · 2018-03-19 · 1 site observation
TERMINATED
A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast CancerNCT03403712 · 2018-03-16 · 1 site observation
COMPLETED
A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant TherapyNCT03321526 · 2017-12-12 · 1 site observation
COMPLETED
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831NCT03201757 · 2017-06-15 · 1 site observation
COMPLETED
A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)NCT03188185 · 2017-06-12 · 1 site observation
COMPLETED
SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and CyclophosphamideNCT02953340 · 2017-05-10 · 1 site observation
COMPLETED
A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)NCT03114657 · 2017-03-29 · 1 site observation
TERMINATED
Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive DisorderNCT03002077 · 2017-02-03 · 1 site observation
COMPLETED
Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive DisorderNCT02972632 · 2016-12-22 · 1 site observation
COMPLETED
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)NCT02973789 · 2016-12-01 · 1 site observation
COMPLETED
A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive DisorderNCT02951988 · 2016-11-13 · 1 site observation
COMPLETED
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)NCT02932943 · 2016-10-15 · 1 site observation
COMPLETED
BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.NCT02788513 · 2016-08-11 · 1 site observation
COMPLETED
A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With SchizophreniaNCT02873208 · 2016-08-07 · 1 site observation
COMPLETED
A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).NCT02670083 · 2016-03-22 · 1 site observation
TERMINATED
A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)NCT02694328 · 2016-03-02 · 1 site observation
COMPLETED
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive DisorderNCT02741791 · 2016-03-01 · 1 site observation
COMPLETED
SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)NCT02643420 · 2016-01-19 · 1 site observation
COMPLETED
Anti-VEGF Treatment for Prevention of PDR/DMENCT02634333 · 2016-01-01 · 1 site observation
COMPLETED
Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)NCT02615002 · 2015-11-01 · 1 site observation
COMPLETED
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's DiseaseNCT02484547 · 2015-09-15 · 1 site observation
TERMINATED
A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)NCT02425891 · 2015-06-23 · 1 site observation
COMPLETED
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and LoperamideNCT02400476 · 2015-02-01 · 1 site observation
COMPLETED
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or PlaceboNCT02192554 · 2014-06-01 · 1 site observation
COMPLETED
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 StudyNCT02158546 · 2014-05-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.